HIGHLIGHTS
- who: Hedong Zhang and colleagues from the Experience from China Department of Kidney Transplantation, The Second Xiangya Hospital of Central South University, Changsha have published the research work: Utilization of HCV Viremic Kidneys with Genotyping/Subtyping- Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China, in the Journal: BioMed Research International 100 eGFR, (mL/minu204e1.73m2) of 30/07/2022
- what: With this, this study was aimed at comparing 1year outcomes in HCV NAT-positive donor kidneys being transplanted to recipients with or without HCV infection in the institution with simplified genotyping/subtyping-free sofosbuvir/velpatasvir . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.